The global rare hemophilia factors market size is anticipated to reach USD
336.3 million by 2025, according to a new report by Grand View Research, Inc.,
progressing at a CAGR of 5.1% during the forecast period. Several factor
concentrates gaining marketing approvals from regulatory bodies such as the
U.S. FDA are expected to provide a significant push to the market. In addition,
growing adoption of prophylaxis treatment by patients is expected to boost the
growth of the market in coming years. Patients with severe rare hemophilia
factor disorders are recommended prophylactic treatment to avoid bleeding
episodes and improve quality of life.
Favorable government initiatives and
mandates to increase diagnosis and treatment rates are escalating the growth of
the market. For instance, the U.S. Congress enacted the Orphan Drug Act (ODA)
in 1983. From 1983 to 2015, around 3,647 drugs were designated the status of
orphan drugs and 554 drugs were approved by the U.S. FDA. Several key market
players in the market are focusing on R&D to launch new products and
solutions for the treatment of rare hemophilia factor disorders. For instance,
in October 2015, FDA approved Coagadex for treatment of hereditary factor X
deficiency. Introduction of new factor concentrates is likely to bolster market
growth over the forecast period.
Full research report on rare hemophilia factors
market analysis: https://www.grandviewresearch.com/industry-analysis/rare-hemophilia-factors-market
Further key findings from the study suggest:
·
Based on type, factor VII accounted for the
largest share in 2016, owing to higher prevalence of this deficiency
·
Factor concentrates is anticipated to be
the most promising segment, registering a CAGR of 5.7% over the forecast
period. This type of treatment is considered to be the safest and most effective
treatment for rare hemophilia factor disorders
·
Fresh frozen plasma is estimated to command
just over 53.0% of the market value by 2025
·
Asia Pacific rare hemophilia factors market
is expected to exhibit the highest CAGR of over 5.5% during the same period.
The growth of the region can be attributed to wide base of population and high
number of consanguineous marriage
·
Some of the key players in the market are
Novo Nordisk; Biogen; Bayer healthcare; Pfizer, Inc.; Baxalta; CSL Behring; and
Bio Products Laboratory Ltd.
View
more reports of this category by Grand View Research at: https://www.grandviewresearch.com/industry/medical-devices
Grand View Research has segmented the global rare hemophilia factors
market on the basis of type, treatment, and region:
Rare Hemophilia Factors Type Outlook
(Revenue, USD Million, 2014 - 2025)
·
Factor I
·
Factor II
·
Factor V
·
Factor VII
·
Factor X
·
Factor XI
·
Factor XIII
Rare Hemophilia Factors Treatment Outlook
(Revenue, USD Million, 2014 - 2025)
·
Factor Concentrates
·
Fresh Frozen Plasma
·
Cryoprecipitate
·
Others
Rare Hemophilia Factors Regional Outlook
(Revenue, USD Million, 2014 - 2025)
·
North America
o
U.S.
o
Canada
·
Europe
o
U.K.
o
Germany
·
Asia Pacific
o
Japan
o
China
·
Latin America
o
Brazil
o
Mexico
·
Middle East and Africa (MEA)
o
South Africa
o
Saudi Arabia
Access press release by Grand View
Research:
https://www.grandviewresearch.com/press-release/global-rare-hemophilia-factors-market
https://www.grandviewresearch.com/press-release/global-rare-hemophilia-factors-market
About Grand View Research
Grand View
Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
